JSM2023
Back to all people

David Ohlssen

Novartis Pharmaceuticals
3 appearances in the program

Sessions & presentations

Can AI/ML shape clinical trials to improve efficiency and help with de-risking drug development?
Invited Paper Session · Mon, Aug 7 , 8:30 AM
Discussant
Estimating Heterogeneous Treatment Effects to Inform Decisions
Presentation: Structured Assessment of Treatment Effect Heterogeneity
Invited Paper Session · Tue, Aug 8 , 8:30 AM
Co-Author
Predictive Modeling for Clinical Trials: Modernizing Health Care for Greater Patient Centricity
Presentation: Combining the three cultures of quantitative decision making in drug development
Invited Paper Session · Wed, Aug 9 , 2:00 PM
Speaker
↑